MENU
SEP 16, 2020 12:15 PM EDT

High-resolution HCA-based phenotypic profiling of tumor spheroids and organoids

Speaker
  • High Throughput Bioscience Center, St. Jude Children's Research Hospital
    Biography
      Dr. Cutrona is a molecular and cellular biologist with expertise in membrane trafficking and image-based HCS/HCA in two- and three-dimensional cell culture systems. After graduating in Biology (1999), she obtained her MASt in genetic anthropology (2001) and her Ph.D for gene regulation studies (2006) at the University of Barcelona (Spain). During her postdoctoral research at the Negri Sud Institute (Italy), from 2007, she conducted a genetic dissection of COPII-vesicles independent protein ER export and membrane trafficking in human cell lines. In 2016, Dr. Cutrona was appointed as a postdoctoral Research Associate at CÚRAM - SFI Centre for Research in Medical Devices and University College Dublin (Ireland) where she developed a HCS/HCA high-resolution imaging platform to dissect complex phenotypes and molecular mechanisms that regulate uptake, traffic and penetrance of synthetic nanoparticles in 3D spheroids. From January 2020, Dr. Cutrona has been appointed as a Staff Scientist at HTB in St. Jude Children's Research Hospital (US), where she studies chemoresistance-triggering pathways in advanced in vitro models of pancreatic ductal adenocarcinoma. She is implementing HCA pipelines to extract quantitative morphological information from organelles to organoids in order to establish phenotypic signatures of chemical and genetic perturbation from primary tumor organoid cultures.

    Abstract

    Image-based high-content screening (HCS) involving cancer cell lines grown in conventional two-dimensional (2D) cell culture, has provided a cornerstone assay for searching new agents to treat pancreatic ductal adenocarcinoma (PDAC). However, since drug response in tumors in vivo is mediated by a myriad of microenvironmental factors (e.g tumor cytoarchitecture and cellular heterogeneity) the search for advanced cellular systems that can recapitulate more closely the tumor context have become a priority. Tumor spheroids consist in clusters obtained from a single cell population (e.g. 2D cell lines), whereas primary organoids can be established as self-organizing complex three-dimensional (3D) structures from cells of tumor resections from patients. All these tumor in-a-dish models better express chemoresistance mechanisms observed in cancers in vivo, and for this reason, they have been incorporated recently into drug HCS pipelines. The challenge now is to systematically visualize and quantitatively analyze chemoresistance-triggering pathways at the subcellular level, for which it will be necessary to engage image-based phenotypic profiling in those ‘tumor avatars’. We have explored the possibility of devising a HCS platform capable to map the spatial distribution of marker proteins to either cells or organelles within the multicellular structures. Here I present a 3D-HCS platform based on miniaturization of 3D culture in optical-bottom multi-well plates, endowed with a HCA-workflow that is effective at capturing cellular and multicellular morphological features in populations of PDAC spheroids and organoids. Our platform provides a perspective for application of this platform for a dissection of drug penetrance determinants.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    Loading Comments...
    Show Resources
    Attendees
    • See more